Safety, Eligibility, and When Sublingual Tirzepatide May Be Appropriate Tirzepatide is not recommended for patients with personal or family history of medullary thyroid carcinoma, multiple endocrine neoplasia type 2, severe renal or hepatic disease, or uncontrolled hypertension
Each week builds on the previous one, progressively addressing the most common mechanisms behind tirzepatide-related musculoskeletal discomfort
Esta es la imagen honesta, no solo un mensaje tranquilizador
Patient-specific factors that influence choice include: Concurrent diabetes : Patients with type 2 diabetes may have broader access through NHS prescribing pathways BMI and weight loss goals : Higher BMI patients may benefit from agents with greater weight loss efficacy Tolerability : Previous experience with gastrointestinal side effects may guide selection Injection preference : Some patients strongly prefer weekly over daily injections, or oral over injectable formulations Cardiovascular disease : Certain GLP-1 agonists have proven cardiovascular benefits, which may be relevant for high-risk patients Ultimately, the choice should be individualised through shared decision-making between patient and clinician, considering the available evidence, licensed indications, local prescribing policies, and patient preferences
Click here to view the full disclosure listing.
Jodie Pepin, clinical pharmacy program director at Harbor Health and an assistant professor of pharmacy at the University of Texas in Austin, explained that millions of people have taken these medications, and the more people who take them, the more likely these associations may occur
